search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Fase I/II study: RAD001 and sorafenib combination in patients with advanced hcc.


- candidate number5470
- NTR NumberNTR1728
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR17-mrt-2009
- Secondary IDsCRAD001O2101 Novartis Pharma
- Public TitleFase I/II study: RAD001 and sorafenib combination in patients with advanced hcc.
- Scientific TitleA Phase I open label/ Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma.
- ACRONYMN/A
- hypothesisHepatocellular Carcinoma (HCC) is the 5th most common solid tumor worldwide. Overall mortality from HCC is high with almost 600,000 deaths worldwide in 2002. Although various chemotherapy regimens are available based on doxorubicin, cisplatin or fluorouracil, traditionally, chemotherapy is not considered an effective treatment scheme for HCC as these tumor are chemoresistent: chemotherapy response rates of 10% can be seen with single agents and up to 20% response rates with combination based regimens. The medical need is high for better systemic therapy for advanced HCC and the limited efficacy of the currently available drug therapies in this population despite the approval of sorafenib (received registration in the European Union for the treatment of HCC in 2007) Mechanism of action of RAD001: the mTOR pathway has been reported to be activated in 15% to 41% of the cases and mTOR inhibitors (RAD001) show antineoplastic activity in HCC models. A combination therapy of RAD001 with sorafenibwhich will target both primary and secondary pathways may be more effective in enhancing cytotoxicity or cytostatic activity, overcoming possible resistance and limiting toxicity.
- Healt Condition(s) or Problem(s) studiedHepatocellular carcinoma
- Inclusion criteria1. Male or female patients ¡İ 18 years old with ability to take oral drugs;
2. Diagnosis of advanced HCC according to the AASLD Guidelines (Bruix and Sherman 2005);
3. HCC stage B or C according to the Barcelona Clinic Liver Cancer (BCLC);
4. No previous systemic therapy for HCC;
5. Measurable disease as per RECIST, that is, at least one lesion that has not been previously treated with local therapy. Previously treated lesions will be considered ¡°non target¡± lesion. Local therapy must be completed at least four weeks prior to baseline scans;
6. Patients with ECOG performance status of 0 or 1;
7. Cirrhotic status of current Child-Pugh class A only (5-6 points) with no encephalopathy. Child-Pugh status should be calculated based on clinical findings and laboratory results during screening period.
- Exclusion criteria1. Patients currently receiving any anti cancer therapy or who have received any local anti cancer therapy ¡Ü4 weeks prior to study treatment start;
2. Active bleeding during the last 30 days;
3. Known previous/current malignancy ¡Ü 3 years except for cervical carcinoma in situ, basal cell carcinoma, superficial bladder carcinoma;
4. Known central nervous system disease;
5. Known history of HIV seropositivity (HIV testing is not mandatory);
6. Any severe and/or uncontrolled medical conditions;
7. Patients receiving chronic treatment with any systemic immunosuppressive agent.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlActive
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 1-jan-2009
- planned closingdate31-mei-2010
- Target number of participants130
- InterventionsPhase I is an open-label, non-randomized, multi-center, designed as a sequential dose-escalation study combining daily RAD001 plus daily sorafenib, after which phase II will be initiated in sequence

Phase II is a randomized, double-blind, parallel, two-arm multi-center study. Randomisation over treatment arms:
1. Sorafenib 400 mg BID + RAD001 (at the phase 1 MTD dose-level);
2. Sorafenib 400 mg BID + placebo to RAD001.
- Primary outcomePhase I:
1. Dose Limiting Toxicities (DLT) of treatment combination of RAD001 plus sorafenib;
2. Pharmacokinetic measures of systemic exposure, such as AUC, Cmax and trough blood levels.

Both Phase I and II:
Efficacy evaluation based on the overall response rate according to RECIST.
- Secondary outcome1. Clinical efficacy in terms of:
A. Objective response rate (ORR);
B. Disease control rate (DCR);
C. Progression-free survival (PFS), according to RECIST.
2. Safety and tolerability: rate and severity of adverse events.
- TimepointsPhase I will be cohort driven with evaluation timepoints after 28 days of treatment. In phase II evaluation will be eventdriven. (time to progression).
- Trial web sitehttp://www.clinicaltrials.gov/ct2/show/NCT00828594
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES H.J. Klümpen
- CONTACT for SCIENTIFIC QUERIES H.J. Klümpen
- Sponsor/Initiator Novartis Pharma
- Funding
(Source(s) of Monetary or Material Support)
Novartis
- PublicationsN/A
- Brief summaryDesign:
Combined Phase I (open-label, designed as a sequential dose-escalation study combining daily RAD001 plus daily sorafenib)and Phase II (randomized, double-blind) trial

Subjects:
patients with advanced hepatocellular carcinoma.

Study medication:
Sorafenib 400 mg BID + RAD001 (at the phase 1 MTD dose-level)

Clinical Phase:
Combined phase I and phase II

Objectives:
Phase 1: Evaluate the safety and tolerability of RAD001 in combination with sorafenib in patients with advance hepatocellular cancer (HCC) and to determine the maximum tolerated dose (MTD).
Phase 2: To estimate the treatment effect as a measure of anti-tumor activity in terms of Time to Progression (TTP) of the combination of RAD001 plus sorafenib, at the MTD, as compared to sorafenib alone.

Primary efficacy variable:
1. Phase I: Dose Limiting Toxicities (DLT) of treatment combination of RAD001 plus sorafenib;
A. Pharmacokinetic measures of systemic exposure, such as AUC, Cmax and trough blood levels.
2. Both Phase I and II: efficacy evaluation based on the overall response rate according to RECIST.

Secondary efficacy variables:
1. Clinical efficacy in terms of: objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), according to RECIST.
2. Safety and tolerability: rate and severity of adverse events.
- Main changes (audit trail)
- RECORD17-mrt-2009 - 14-sep-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl